UM
CPRX

UniSuper Management’s Catalyst Pharmaceutical CPRX Stock Holding History

UniSuper Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-28,265
Closed -$438K – 769
2024
Q2 		$438K Hold
28,265
– – ﹤0.01% 816
2024
Q1 		$451K Buy
+28,265
New +$426K ﹤0.01% 781

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

UniSuper Management's CPRX Position: Q3 2024 in Review

UniSuper Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2024, closing a stake of 28,265 shares — an estimated $438K sold.

UniSuper Management first reported a position in CPRX in Q1 2024 and held it in 2 quarters. The position peaked at $451K in Q1 2024. 316 funds tracked by Wall St. Rank hold CPRX as of Q3 2024.

  • UniSuper Management reported no remaining Catalyst Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • UniSuper Management sold 28,265 Catalyst Pharmaceutical shares in Q3 2024, an estimated $438K.
  • UniSuper Management first reported a position in Catalyst Pharmaceutical in Q1 2024 and held it in 2 quarters.
  • UniSuper Management's Catalyst Pharmaceutical position peaked at $451K in Q1 2024.
  • 316 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2024.

Based on UniSuper Management's 13F filing for Q3 2024, filed 14 Nov 2024.